| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), LGND's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 188.9K | $34.72M | - | |
| Dir | 102.6K | $25.64M | - | |
| Dir | 41.8K | $2.90M | - | |
| Other | 41.4K | $2.16M | - | |
| Dir | 27.0K | $6.67M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Kozarich John W55 | Director | Sell10b5-1 | 467 | $200.50 | $93,632.37 | -1.1% | +13.4% | - | |
| Feb 2, 2026 | Kozarich John W55 | Director | Sell10b5-1 | 467 | $195.91 | $91,490.04 | -1.1% | +15.4% | - | |
| Jan 2, 2026 | Kozarich John W55 | Director | Sell10b5-1 | 467 | $189.58 | $88,532.49 | -1.1% | +5.0% | - | |
| Dec 12, 2025 | Espinoza Octavio48 | Chief Financial Officer | Sell | 1,804 | $188.31 | $339,711.24 | -6.4% | +11.6% | - | |
| Dec 1, 2025 | Kozarich John W55 | Director | Sell10b5-1 | 467 | $195.84 | $91,456.89 | -1.0% | +2.8% | - | |
| Nov 7, 2025 | Gray Nancy Ryan | Director | Sale+OE | 6,571 | $205.45 | $1,350,011.95 | -44.8% | -5.3% | - | |
| Nov 7, 2025 | Lamattina John L | Director | Sale+OE | 4,179 | $205.45 | $858,575.55 | -12.0% | -5.3% | - | |
| Nov 3, 2025 | Kozarich John W55 | Director | Sell10b5-1 | 467 | $191.05 | $89,219.01 | -1.0% | +3.5% | - | |
| Oct 1, 2025 | Kozarich John W55 | Director | Sell10b5-1 | 467 | $179.44 | $83,800.34 | -1.0% | +6.2% | +69.1% | |
| Sep 23, 2025 | Aryeh Jason | Director | Sell | 10,000 | $170.81 | $1,708,087.72 | -12.6% | +16.0% | +74.9% |